KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models

Launched by KNOWN MEDICINE, INC. · Apr 18, 2022

Keywords

ClinConnect Summary

The KM3D Multicenter Cancer Consortium is a clinical trial designed to help doctors predict how well certain cancer treatments will work for patients. This study uses a special method called 3D cell culture models, which allows researchers to grow small samples of tumors in a lab. By doing this, they hope to see if the way these tumor samples respond to drugs can tell us how the actual patient’s cancer will respond to the same treatments. This trial is currently looking for participants who have a solid tumor cancer that needs to be surgically removed, biopsied, or drained, and who are over 18 years old.

If you join this study, you would need to provide a tissue sample from your tumor, which must be sent to the researchers within 24 hours of being removed. You will also be asked to give permission for your medical history related to cancer treatments to be shared, but your personal information will remain private. It's important to note that some people might not be eligible to participate if they have certain health conditions, as determined by the study doctors. Overall, this trial aims to improve cancer treatment outcomes by better understanding how different drugs work for individual patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A demonstrated primary solid cancer for which it is medically indicated and planned to be surgically resected, biopsied, or drained (via malignant pleural effusion).
• • The ability to ship the tissue sample within 24 hours of removal from the patient.
• • Signed and dated consent to giving tissue as well as allowing for de-identified medical history information regarding administered treatments and treatment outcomes to be shared.
• • over 18 years of age
• Exclusion Criteria:
• • Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation in the opinion of the Investigator.